AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21847611
Drug: Low-low: 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-low: 1.6 g BA/day for 8 weeks
Trial: 7547157
Drug: Loperamide oxide
RxNorm normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide oxide 2 mg
Trial: 7547157
Drug: Loperamide 2
RxNorm normalized name: loperamide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 2 mg
Trial: 2206069
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (up to 3 gm/hr)
Trial: 2206069
Drug: No tocolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tocolytic therapy (control)
Trial: 6767944
Drug: bezafibrate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (3 x 200 mg/day)
Trial: 6767944
Drug: discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: discontinuation of bezafibrate
Trial: 31928611
Drug: Biological with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological with best-practice prevention (sealing-in decay, selective carious tissue removal and fissure sealants)
Trial: 31928611
Drug: Best-practice prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best-practice prevention alone (dietary and toothbrushing advice, topical fluoride and fissure sealing of permanent teeth)
Trial: 31928611
Drug: Biological arm
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological arm vs Conventional arm
Trial: 24566991
Drug: Twice-a-week supervised
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-week supervised aerobic and resistance training plus exercise counseling (EXE)
Trial: 22657950
Drug: AXOS-enriched breads
RxNorm normalized name: Rhizopus stolonifer allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXOS-enriched breads (2.2 g AXOS)
Trial: 19947803
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (57 patients)
Trial: 17697451
Drug: Pegfilgrastim (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (100 microg/kg or a fixed dose of 6 mg)
Trial: 15103534
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) delivered by trained social workers
Trial: 11153777
Drug: PET-guided management
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-guided management (n=49; 12 PTCA, 14 CABG, 23 drug therapy)
Trial: 11153777
Drug: SPECT-guided management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT-guided management (n=54; 15 PTCA, 13 CABG, 26 drug therapy)
Trial: 9663912
Drug: Lisinopril treatment
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril treatment after 3 and 12 months
Trial: 9663912
Drug: Lisinopril plus
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril plus hydrochlorothiazide treatment after 3 and 12 months
Trial: 9663912
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment after a final 4-week period
Trial: 2839321
Drug: Methylcellulose 4
RxNorm normalized name: methylcellulose 475 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose 4 g
Trial: 2839321
Drug: Methylcellulose 1
RxNorm normalized name: methylcellulose 1500cps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose 1 g, 2 g, or 4 g
Trial: 16303008
Drug: Low-dose sirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sirolimus (SRL) with low-dose MMF
Trial: 16303008
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine (CsA) with low-dose MMF
Trial: 28686771
Drug: Clindamycin-BP 3.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-BP 3.75% aqueous gel, once-daily for 12 weeks
Trial: 28686771
Drug: Clindamycin-BP 3.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-BP 3.75% aqueous gel, continued treatment for a further 12 weeks for patients with ≥50% reduction in total lesion count
Trial: 28686771
Drug: Clindamycin-BP 3.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-BP 3.75% aqueous gel
Trial: 23400620
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (152 mg/d vitamin C and 50 mg/d vitamin E)
Trial: 16565956
Drug: VBMCP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBMCP and high‐dose cyclophosphamide
Trial: 14693058
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) 3.5 g/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Trial: 14693058
Drug: Etoposide (VP-16)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide (VP-16) 1000 mg/m(2) or 1500 mg/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Trial: 11075314
Drug: Rosiglitazone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (2 mg every 12 hours)
Trial: 11075314
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg every 12 hours)
Trial: 11075314
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rosiglitazone and metformin
Trial: 11075314
Drug: Rosiglitazone and
RxNorm normalized name: Rosiglitazone and Glimepiride Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone and metformin (alone or in combination)
Trial: 9345020
Drug: SCF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCF plus G‐CSF
Trial: 9345020
Drug: SCF pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCF pretreatment followed by SCF plus G‐CSF
Trial: 9345020
Drug: Control (G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (G‐CSF alone)
Trial: 8177925
Drug: Piracetam (2.9,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (2.9, 4.8, and 9.6 g Nootropil UCB)
Trial: 24351534
Drug: Glutamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.3 g/kg protein in the form of glutamine dipeptide for 10 days)
Trial: 24351534
Drug: Glutamine combined
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine combined with ulinastatin (0.3 g/kg protein in the form of glutamine dipeptide for 10 days + intravenous injection of 100 kU ulinastatin every 8 hours for 7 days)
Trial: 18156400
Drug: 7.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g/d DHA oil (3 g DHA/d)
Trial: 12620949
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) with 0.15 mL x kg(‐1) x hr(‐1) 0.2% ropivacaine
Trial: 12620949
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA) with 5 mL single bolus application of R or BS every 20 min
Trial: 28266704
Drug: EO/LP solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); applied thrice with 7-day intervals
Trial: 28266704
Drug: EO/LP solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); single application
Trial: 28266704
Drug: P/PB mousse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P/PB mousse (pyrethrins and piperonyl butoxide); applied twice with a 7-day interval
Trial: 24655542
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (eight sessions over 4 weeks)
Trial: 24655542
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (after a 4-week waiting period)
Trial: 22446143
Drug: ongoing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ongoing treatment
Trial: 3476513
Drug: Oral rinse
RxNorm normalized name: Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse containing 300 micrograms/ml sanguinaria extract
Trial: 3476513
Drug: Supragingival irrigation
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAGINGIVAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supragingival irrigation with dilute solutions of sanguinaria (22.5 micrograms/ml and 90 micrograms/ml)
Trial: 26354567
Drug: Atorvastatin (intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (intervention group)
Trial: 16798445
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine with fentanyl 2 microg/mL (RF-group)
Trial: 12884990
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 10 mg and fentanyl 25 microg (upright for 15 min)
Trial: 12884990
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 15 mg (immediately positioned supine)
Trial: 8827897
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K1 (N = 13)
Trial: 8827897
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin K1 (N = 16)
Trial: 26365555
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (cholecalciferol) 100,000 IU (2.5 mg) monthly for an estimated median of 3.3 years (range 2.5‐4.2 years)
Trial: 12637463
Drug: Bexarotene 200
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene 200 mg/m²/d
Trial: 12637463
Drug: Bexarotene 500
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene 500 mg/m²/d
Trial: 10593328
Drug: Oral immunonutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunonutrition (an arginine‐, RNA‐, and omega3 fatty acid‐supplemented diet) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Trial: 10593328
Drug: Isoenergetic control
RxNorm normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic control diet (1 L/d) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Trial: 1860327
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 5 micrograms/kg.min
Trial: 1860327
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 10 micrograms/kg.min
Trial: 1860327
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at all three rates (2.5, 5, and 10 micrograms/kg.min)
Trial: 6839635
Drug: Cimetidine 1200
RxNorm normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1200 mg a day
Trial: 6839635
Drug: Cimetidine 2400
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 2400 mg a day
Trial: 31107300
Drug: Nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside reverse transcriptase inhibitors
Trial: 26805558
Drug: 20 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 minutes post-infusion scalp cooling
Trial: 26805558
Drug: 45 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 minutes post-infusion scalp cooling
Trial: 20073213
Drug: Integrative Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Chinese and Western medicine (Yuntu recipe)
Trial: 20073213
Drug: Western medical
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medical supportive treatment (fluid infusion)
Trial: 8304565
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg pentamidine isethionate, administered in four every-other-day injections
Trial: 8304565
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg pentamidine isethionate, administered in four every-other-day injections
Trial: 8304565
Drug: Standard Glucantime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Glucantime therapy
Trial: 28765032
Drug: Swaddling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swaddling with oral administration of 0.2 ml of 24% sucrose
Trial: 28765032
Drug: Swaddling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swaddling with oral administration of breast milk
Trial: 28765032
Drug: Swaddling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swaddling with oral administration of distilled water (control)
Trial: 22965458
Drug: Low-dose spinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spinal anaesthesia (8-mg hyperbaric bupivacaine 0.5% with fentanyl 20 μg)
Trial: 8554246
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy with 3 or more daily insulin injections or continuous subcutaneous insulin infusion, guided by 4 or more glucose tests per day
Trial: 8554246
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with 1 or 2 daily insulin injections
Trial: 1992534
Drug: 480 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg/d megestrol acetate
Trial: 1992534
Drug: 960 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg/d megestrol acetate
Trial: 1992534
Drug: Low-dose megestrol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose megestrol acetate
Trial: 6411382
Drug: Topical cromoglycates
RxNorm normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical cromoglycates
Trial: 28953501
Drug: Neostigmine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 40 μg/kg
Trial: 14617222
Drug: Lispro insulin
RxNorm normalized name: Lispro insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lispro insulin + NPH insulin
Trial: 14617222
Drug: Lispro insulin
RxNorm normalized name: Lispro insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lispro insulin + metformin
Trial: 14617222
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin + NPH insulin
Trial: 10685722
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg (Ate)
Trial: 9086133
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day hydroxyurea
Trial: 9086133
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day hydroxyurea
Trial: 9086133
Drug: Control (didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (didanosine therapy only)
Trial: 30664008
Drug: Subcutaneous interferon‐α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon‐α (IFN‐α) 9×10 IU/m, n=125
Trial: 30664008
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous interleukin-2 (IL‐2) 9×10 IU/m, n=125
Trial: 30664008
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous interleukin-2 (IL‐2), n=125
Trial: 30664008
Drug: Subcutaneous interferon‐α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon‐α (IFN‐α), n=125
Trial: 30040818
Drug: Tailored multifaceted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored multifaceted intervention (n = 154) including physiotherapist-led vestibular rehabilitation (35%), internet-based cognitive-behavioral therapy (19%), Otago home-based exercise program (24%), and medical management (40%)
Trial: 23788468
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) with intravenous (IV) fentanyl
Trial: 19995933
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tafenoquine
Trial: 19995933
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg mefloquine
Trial: 17976222
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg po/d, given for 6‐8 days before surgery)
Trial: 16629348
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150 to 300 mg daily)
Trial: 14667956
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of rosuvastatin 40 mg
Trial: 14667956
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of rosuvastatin 8 mg over 4 hours
Trial: 11027740
Drug: Budesonide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (mean daily dose of 412 microg, mean cumulative dose of 1.35 g over 9.2 years)
Trial: 11027740
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (asthma patients who never received inhaled corticosteroids)
Trial: 9203786
Drug: Erythromycin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (50 mg/kg per day in four divided doses)
Trial: 9203786
Drug: Trimethoprim-sulphamethoxazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulphamethoxazole (10 mg/kg per day of trimethoprim and 50 mg/kg per day of sulphamethoxazole in two divided doses for five days)
Trial: 1306084
Drug: Supro isolated
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supro isolated soy protein (1.5 g/kg/day, 8 weeks)
Trial: 3511977
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of E. coli AZ (group A)
Trial: 3511977
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) receiving no administration
Trial: 31884246
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (placebo)
Trial: 29885082
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (RSV) 500 mg 3 times daily for 6 months
Trial: 21451421
Drug: Eplerenone (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (100-300 mg once daily)
Trial: 21451421
Drug: Spironolactone (75-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (75-225 mg once daily)
Trial: 12378634
Drug: OAM: metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM: metronidazole 500 mg bid, amoxicillin 1 g bid, omeprazole 20 mg bid
Trial: 12378634
Drug: OAA: azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAA: azithromycin 1 g od for the first 3 days, amoxicillin 1 g bid, omeprazole 20 mg bid
Trial: 12492615
Drug: In-patient pharmaceutical
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-patient pharmaceutical counselling with MIDS and medicine reminder card
Trial: 30944269
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg/d
Trial: 18823203
Drug: Evolved agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolved agent
Trial: 16332231
Drug: beta‐TCP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐TCP + 0.3 mg/ml rhPDGF‐BB in buffer
Trial: 16332231
Drug: beta‐TCP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐TCP + 1.0 mg/ml rhPDGF‐BB in buffer
Trial: 12215691
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intravenous ketoprofen 30 minutes before surgical incision (Group I)